03-16-06

Express Mail Label No. EV775568196

SIU 7397 PATENT HW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication of Kathleen C.M. Campbell

Art Unit 1614

Serial No. 10/694,436

Filed October 27, 2003

Confirmation No. 8942

For

THERAPEUTIC USE OF METHIONINE FOR THE TREATMENT

OR PREVENTION OF MUCOSITIS

Examiner Shirley V. Gembeh

March 15, 2006

COMMISSIONER FOR PATENTS

SIR:

FORTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing of this Information Disclosure Statement.

Attached are references concerning cisplatin.

Applicant reiterates the observation that, for example, a patient receiving treatment with an anti-tumor platinum-coordination compound could develop ototoxicity, neurotoxicity, weight loss, and alopecia, yet not inevitably develop mucositis.

Respectfully submitted,

anet S. Hendrickson, Ph.D., Reg. No. 55,258

SENNIGER, POWERS

One Metropolitan Square, 16th Floor

St. Louis, Missouri 63102

(314) 231-5400

			70				
PTO/SB/08A , MAR 1 5 2006 g				Complete if Known			
		\~0~	AL I	Application Number	10/694,436		
INFORMATION DISCLOSURE STATEMENT BY APPENDANT				Filing Date	October 27, 2003		
				Confirmation Number	8942		
				First Named Inventor	Kathleen C.M. Campbell		
(use as many sheets as necessary)				Group Art Unit	1614		
				Examiner Name	Shirley V. Gembeh		
Sheet	1	of	1	Attorney Docket No.	SIU 7397		

		-	U.S.	PATENT	DOCUMENTS				
Examiner Initials*	Cite No. ¹	U.S. Patent Docume		ent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
			FOREI	GN PATE	NT DOCUMENTS	·			
-		Foreign Patent Document							
Examiner Initials	Cite No. ¹	Office	Number⁴	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶		
		OTHE	R ART – NON	I PATENT	LITERATURE DOCUMEN	rs			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published							
	31	EPSTEIN, Current Developments in Treating Chemotherapy-Related Oral Mucositis, Clinical Advances in Hematology & Oncology, 1(12):712-713.							
	32	VON DER MAASE et al., Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study, Journal of Clinical Oncology, 17(17):3068-3077.							
Examiner					Date				

Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Applicant is to place a check mark here if English Translation is attached or place an "A" here if English language abstract is attached.